Interval dynamics of transplantability for hepatocellular carcinoma after primary curative resection: risk factors for nontransplantable recurrence

Llovet, 2021, Hepatocellular carcinoma, Nat Rev Dis Prim, 7, 6, 10.1038/s41572-020-00240-3 Cherqui, 2009, Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation, Ann Surg, 250, 738, 10.1097/SLA.0b013e3181bd582b Sapisochin, 2017, Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches, Nat Rev Gastroenterol Hepatol, 14, 203, 10.1038/nrgastro.2016.193 Omata, 2017, Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update, Hepatol Int, 11, 317, 10.1007/s12072-017-9799-9 2018, Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 69, 182, 10.1016/j.jhep.2018.03.019 Marrero, 2018, Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases, Hepatology, 68, 723, 10.1002/hep.29913 Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104 Mazzaferro, 2018, Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma, Gastroenterology, 154, 128, 10.1053/j.gastro.2017.09.025 Gorgen, 2019, Patterns and predictors of mortality after waitlist dropout of patients with hepatocellular carcinoma awaiting liver transplantation, Transplantation, 103, 2136, 10.1097/TP.0000000000002616 Toso, 2012, A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list, Hepatology, 56, 149, 10.1002/hep.25603 Geissler, 2009, Immunosuppression for liver transplantation, Gut, 58, 452, 10.1136/gut.2008.163527 Thuluvath, 2021, Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases, J Hepatol, 75, 1434, 10.1016/j.jhep.2021.08.008 Park, 2015, Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study, Liver Int, 35, 2155, 10.1111/liv.12818 Poon, 2002, Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation, Ann Surg, 235, 373, 10.1097/00000658-200203000-00009 Ho, 2016, Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-Pacific primary liver cancer expert meeting (APPLE 2014), Liver Cancer, 5, 245, 10.1159/000449336 Minagawa, 2022, Anatomic resection for hepatocellular carcinoma: prognostic impact assessed from recurrence treatment, Ann Surg Oncol, 29, 913, 10.1245/s10434-021-10380-9 Kim, 2020, Predicting hepatocellular carcinoma recurrence beyond Milan criteria after liver resection for solitary hepatocellular carcinoma, J Gastrointest Surg, 24, 2219, 10.1007/s11605-019-04363-1 Gelli, 2020, Liver resection for early hepatocellular carcinoma: preoperative predictors of non transplantable recurrence and implications for treatment allocation, Ann Surg, 272, 820, 10.1097/SLA.0000000000004259 Zheng, 2017, Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection: validation of a clinical risk score in an international cohort, Ann Surg, 266, 693, 10.1097/SLA.0000000000002360 Tsilimigras, 2020, Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer criteria, Ann Surg Oncol, 27, 2321, 10.1245/s10434-020-08452-3 Hwang, 2007, Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma, Liver Transplant, 13, 741, 10.1002/lt.21157 Belghiti, 2003, Resection prior to liver transplantation for hepatocellular carcinoma, Ann Surg, 238, 885, 10.1097/01.sla.0000098621.74851.65 Kim, 2008, Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk, Transplant Proc, 40, 3558, 10.1016/j.transproceed.2008.03.175 Ho, 2013, Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma, Ann Surg Oncol, 20, 2526, 10.1245/s10434-013-2940-7 Yao, 2001, Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival, Hepatology, 33, 1394, 10.1053/jhep.2001.24563 Ho, 2009, Liver resection improves the survival of patients with multiple hepatocellular carcinomas, Ann Surg Oncol, 16, 848, 10.1245/s10434-008-0282-7 Dindo, 2004, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 240, 205, 10.1097/01.sla.0000133083.54934.ae Hong, 2017, Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma, Tumour Biol, 39, 10.1177/1010428317720863 Ho, 2020, Survival after treatable hepatocellular carcinoma recurrence in liver recipients: a nationwide cohort analysis, Front Oncol, 10 Groeschl, 2013, Ablation for hepatocellular carcinoma: validating the 3-cm breakpoint, Ann Surg Oncol, 20, 3591, 10.1245/s10434-013-3031-5 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 10.1080/01621459.1999.10474144 Tabrizian, 2015, Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis, Ann Surg, 261, 947, 10.1097/SLA.0000000000000710 Mehta, 2019, Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: implications for organ allocation, Am J Transplant, 19, 2210, 10.1111/ajt.15353 Lai, 2021, Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant, JAMA Surg, 156, 10.1001/jamasurg.2021.3112 Di Sandro, 2019, Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases, Updates Surg, 71, 285, 10.1007/s13304-019-00649-w Tsilimigras, 2019, Prognosis after resection of Barcelona clinic liver cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification, Ann Surg Oncol, 26, 3693, 10.1245/s10434-019-07580-9 Furukawa, 2017, Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona clinic liver cancer classification, J Hepatobiliary Pancreat Sci, 24, 199, 10.1002/jhbp.436 Ikegami, 2008, The timing of liver transplantation after primary hepatectomy for hepatocellular carcinoma: a special reference to recurrence pattern and Milan criteria, Transplantation, 86, 641, 10.1097/TP.0b013e3181814de2 Kim, 2019, Prognostic markers affecting the early recurrence of hepatocellular carcinoma with liver cirrhosis after curative resection, Int J Biol Markers, 34, 123, 10.1177/1724600819834306 Erstad, 2019, Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma, Ann Surg Oncol, 26, 1474, 10.1245/s10434-019-07227-9 Nakagawa, 2021, Four gene intrahepatic metastasis-risk signature predicts hepatocellular carcinoma malignant potential and early recurrence from intrahepatic metastasis, Surgery, 169, 903, 10.1016/j.surg.2020.09.032 Sugimachi, 2001, Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma, J Hepatobiliary Pancreat Surg, 8, 410, 10.1007/s005340100002 Lee, 2014, Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation, Liver Transplant, 20, 1057, 10.1002/lt.23919 Serenari, 2021, The Impact of time interval between hepatic resection and liver transplantation on clinical outcome in patients with hepatocellular carcinoma, Cancers, 13, 10.3390/cancers13102398 Brown, 2019, Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy, Hepatology, 70, 1437, 10.1002/hep.30633 Rodriguez-Peralvarez, 2013, A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability, Ann Surg Oncol, 20, 325, 10.1245/s10434-012-2513-1 Halazun, 2017, Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the Story, Ann Surg, 265, 557, 10.1097/SLA.0000000000001966 Wang, 2021, The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma, Sci Rep, 11, 2415, 10.1038/s41598-021-82058-x Lee, 2021, Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation, Ann Surg, 273, 564, 10.1097/SLA.0000000000003268 Liu, 2021, Predicting microvascular invasion in hepatocellular carcinoma: a deep learning model validated across hospitals, Cancer Imag, 21, 56, 10.1186/s40644-021-00425-3 Poon, 2000, Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis, J Clin Oncol, 18, 1094, 10.1200/JCO.2000.18.5.1094 Yasuda, 2020, Liver regeneration after major liver resection for hepatocellular carcinoma in the elderly, J Invest Surg, 33, 332, 10.1080/08941939.2018.1517839 Dahiya, 2010, Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience, Surgery, 147, 676, 10.1016/j.surg.2009.10.043 Vibert, 2020, Advances in resection and transplantation for hepatocellular carcinoma, J Hepatol, 72, 262, 10.1016/j.jhep.2019.11.017 Ruiz, 2021, Monosegment associating liver partition and portal vein ligation for staged hepatectomy: preserving segment 1 as the only liver remnant after hepatocellular carcinoma recurrence, Ann Hepatobiliary Pancreat Surg, 25, 562, 10.14701/ahbps.2021.25.4.562 Siriwardana, 2012, Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study, World J Surg, 36, 1640, 10.1007/s00268-012-1522-3 Ali, 2017, Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection, Eur J Nucl Med Mol Imag, 44, 2195, 10.1007/s00259-017-3792-3 Hasegawa, 2005, Prognostic impact of anatomic resection for hepatocellular carcinoma, Ann Surg, 242, 252, 10.1097/01.sla.0000171307.37401.db Ahn, 2013, A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function, Eur J Surg Oncol, 39, 964, 10.1016/j.ejso.2013.06.019 Ho, 2012, Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria, Ann Surg Oncol, 19, 826, 10.1245/s10434-011-1975-x Chien, 2019, Taiwan consensus statement on the management of chronic hepatitis B, J Formos Med Assoc, 118, 7, 10.1016/j.jfma.2018.11.008 Chang, 2013, National antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in Taiwan: a preliminary report, Med Care, 51, 908, 10.1097/MLR.0b013e3182a502ba Liao, 2021, Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan, J Hepatol, 75, 132, 10.1016/j.jhep.2021.02.029 Chiang, 2015, Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan, Hepatology, 61, 1154, 10.1002/hep.27630 Gao, 2020, Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis, Eur J Gastroenterol Hepatol, 32, 1207, 10.1097/MEG.0000000000001639 Zhang, 2015, Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma, World J Gastroenterol, 21, 3860, 10.3748/wjg.v21.i13.3860 Singal, 2010, Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma, Aliment Pharmacol Ther, 32, 851, 10.1111/j.1365-2036.2010.04414.x Ikeda, 2017, Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma, Dig Dis Sci, 62, 2932, 10.1007/s10620-017-4739-z Wang, 2020, Early and late recurrence of hepatitis B virus-associated hepatocellular carcinoma, Oncologist, 25, e1541, 10.1634/theoncologist.2019-0944 Chiang, 2008, Focal gains of VEGFA and molecular classification of hepatocellular carcinoma, Cancer Res, 68, 6779, 10.1158/0008-5472.CAN-08-0742 Dominguez, 2020, Impact of next-generation sequencing on outcomes in hepatocellular carcinoma: how precise are We really?, J Hepatocell Carcinoma, 7, 33, 10.2147/JHC.S217948 Harding, 2019, Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies, Clin Cancer Res, 25, 2116, 10.1158/1078-0432.CCR-18-2293 Llovet, 2018, Molecular therapies and precision medicine for hepatocellular carcinoma, Nat Rev Clin Oncol, 15, 599, 10.1038/s41571-018-0073-4 Duvoux, 2012, Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria, Gastroenterology, 143, 986, 10.1053/j.gastro.2012.05.052